Streetbeat News

Analyst Ratings

ZIM

B of A Securities analyst Muneeba Kayani has maintained an Underperform rating on ZIM Integrated Shipping (NYSE:ZIM) but increased the price target from $6.4 to $10.5.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 4:06 pm

BCC

Truist Securities analyst Michael Roxland has reaffirmed a Buy rating on Boise Cascade (NYSE:BCC) and increased the price target from $126 to $156. This adjustment reflects a positive outlook on the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 4:04 pm

IP

Truist Securities analyst Michael Roxland has reaffirmed a Buy rating on International Paper (NYSE:IP) and increased the price target from $40 to $46.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 4:02 pm

GHLD

JP Morgan analyst Richard Shane has maintained a Neutral rating on Guild Holdings (NYSE:GHLD) and increased the price target from $12 to $14.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 4:02 pm

RVTY

Revvity (NYSE:RVTY) has been evaluated by 7 analysts over the last three months, with a mix of bullish to bearish sentiments. The average 12-month price target is now $112.29, down from $131.33, with a high estimate of $135.00 and a low of $95.00. Analysts from firms like Evercore ISI Group, Wells Fargo, Raymond James, Goldman Sachs, Keybanc, and JP Morgan have adjusted their ratings and price targets, reflecting changes in market conditions and company performance. Revvity operates in diagnostics and discovery/analytical solutions, serving various markets. Financially, the company has a lower market cap compared to industry averages, a negative revenue trend, a high net margin, but lower ROE and ROA than industry benchmarks, and a conservative debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

January 04, 2024 | 4:01 pm

RYTM

Rhythm Pharmaceuticals (NASDAQ:RYTM) has been the subject of diverse analyst opinions over the past three months, with 7 analysts offering ratings that range from bullish to indifferent. The average 12-month price target for RYTM has increased by 21.7% to $44.86, with a high estimate of $55.00 and a low of $29.00. Analysts from firms including Needham, Morgan Stanley, Wells Fargo, and Goldman Sachs have raised their price targets for RYTM, reflecting a positive outlook on the company's performance. Rhythm Pharmaceuticals is a biopharmaceutical company focused on developing therapies for rare diseases, with setmelanotide (RM 493) as its lead product candidate. The company has shown a significant revenue growth rate of 425.3% as of September 30, 2023, but has a net margin of -196.25% and an ROE of -23.26%, indicating challenges in profitability and equity returns.

Portfolio Pulse from Benzinga Insights

January 04, 2024 | 4:01 pm

CI

Analysts have provided varied ratings for Cigna Group (NYSE:CI) over the last quarter, with recent updates showing a mix of 'Maintain', 'Raise', and 'Outperform' recommendations. The average 12-month price target for CI has increased to $340.43, up from $324.00, with a high estimate of $372.00 and a low of $327.00. Cigna's financials indicate strong market presence, revenue growth, and efficient cost management, with a market cap above industry benchmarks, a positive revenue trend, and a net margin of 2.87%. The company's ROE and ROA also surpass industry standards, and it has a conservative debt-to-equity ratio of 0.68.

Portfolio Pulse from Benzinga Insights

January 04, 2024 | 4:00 pm

CHGG

Chegg's stock price is trading lower following a negative report published by The Bear Cave.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 4:00 pm

ALKT

Alkami Technology (NASDAQ:ALKT) has been analyzed by 5 analysts, showing a shift towards a more positive outlook with an average 12-month price target of $24.00, up from $21.25. Analysts from Barclays, Stephens & Co., JMP Securities, JP Morgan, and Needham have adjusted their ratings and price targets, reflecting changes in market conditions and company performance. Alkami's financials indicate strong revenue growth but below-average profitability and efficiency metrics. The company's low debt-to-equity ratio suggests a healthy balance of financing.

Portfolio Pulse from Benzinga Insights

January 04, 2024 | 4:00 pm

WDAY

Workday (NASDAQ:WDAY) has received diverse analyst ratings over the last three months, with a shift towards more bullish sentiment in the last 30 days. The average 12-month price target for WDAY is now $282.72, up from the previous $255.94. Analysts from firms like Keybanc, Piper Sandler, and Morgan Stanley have raised their price targets, reflecting optimism about the company's performance. Workday's financial health indicators show a strong market presence with a market cap above industry average, a positive revenue trend with a growth rate of 16.67%, but challenges in profitability and asset utilization with lower than industry average net margin, ROE, and ROA.

Portfolio Pulse from Benzinga Insights

January 04, 2024 | 4:00 pm